Clostridium difficile infection (CDI) is featured as the dysbiosis of gut microbiota and consequent mild diarrhoea or severe pseudomembranous colitis. However, the frequent recurrence of CDI following treatment course challenged the antibiotic therapy. Currently, to address the relapse of CDI, several novel therapeutic approaches have emerged, including Bezlotoxumab, SYN-004 (Ribaxamase), RBX2660, and faecal microbial transplant. Traditional Chinese Medicine (TCM) is an old medical system accumulated for thousands of years. Orientated by syndrome-based treatment, TCM functions in a multicomponent and multitarget mode. This old medical system showed superiority over conventional medical treatment, particularly in the treatment of complex disorders, including CDI. In the present review, we will elaborate the TCM intervention in the management of CDI and others disorders via restoring the gut microbiota dysbiosis. We hope that this review will deepen our understanding of TCM as an alternative to CDI treatment. However, more rigorously designed basic researches and randomised controlled trials need to conduct to appraise the function mechanisms and effects of TCM. Finally, it is concluded that the combined therapeutic potentials of TCM and western medicine could be harness to resolve the recurrence and improve the outcome of CDI.

艰难梭菌感染（CDI）的特征是肠道菌群营养不良，继而出现轻度腹泻或严重的伪膜性结肠炎。然而，治疗过程后CDI的频繁复发对抗生素治疗提出了挑战。当前，为了解决CDI的复发，已经出现了几种新颖的治疗方法，包括贝洛酮单抗，SYN-004（核糖酰胺酶），RBX2660和粪便微生物移植。中医（TCM）是一种累积了数千年的古老医疗系统。通过基于综合症的治疗，中医以多组分和多靶点模式发挥作用。这种旧的医疗系统显示出优于常规医疗的优势，特别是在包括CDI在内的复杂疾病的治疗中。在目前的评论中，我们将通过恢复肠道菌群失调来阐述中医药在CDI和其他疾病管理中的干预措施。我们希望这次审查能加深我们对中药替代CDI治疗的理解。然而，需要进行更严格设计的基础研究和随机对照试验来评估中药的功能机制和作用。最后，得出的结论是，中西医结合治疗的潜力可用于解决复发和改善CDI的结果。